India: Jubilant Life Sciences exploring Singapore IPO for pharma unit

Jubilant Life Sciences Ltd., a roughly $2 billion India-based drug company, is considering a Singapore initial public offering of its pharmaceuticals subsidiary, according to people with knowledge of the matter.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.